3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Myelodysplastic Syndromes
159
Leukemia, Myeloid, Acute
141
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
67
Myeloproliferative Disorders
64
Precursor Cell Lymphoblastic Leukemia-Lymphoma
52
Primary Myelofibrosis
47
Leukemia, Myelomonocytic, Chronic
40
Lymphoma, Non-Hodgkin
36
Leukemia
26
Polycythemia Vera
23
Hodgkin Disease
23
Myelodysplastic-Myeloproliferative Diseases
21
Multiple Myeloma
20
Thrombocythemia, Essential
19
Hematologic Neoplasms
19
Leukemia, Lymphocytic, Chronic, B-Cell
18
Neoplasms
17
Leukemia, Biphenotypic, Acute
15
Anemia, Refractory, with Excess of Blasts
14
Sarcoma
13
Histiocytosis, Langerhans-Cell
13
Glioma
13
Neuroblastoma
12
Hematologic Diseases
12
Wilms Tumor
11
Rhabdoid Tumor
11
Recurrence
11
Osteosarcoma
11
Neuroectodermal Tumors, Primitive, Peripheral
11
Medulloblastoma
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms, Connective Tissue
×
Myeloid
×
90 days
×
Clear all
NCT04996875
2026-05-05
APEX
Cogent Biosciences, Inc.
Phase 2
Recruiting
140 enrolled